

REF: MDOL/CS-SE/2025- 26/048

January 15, 2026

To,

Listing Department

BSE Ltd

1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

Scrp Code: 532637

Listing Department

National Stock Exchange of India Limited

“Exchange Plaza”, 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051

Symbol: MANGALAM

Sub: Outcome of the Board Meeting held on Thursday, January 15, 2026

Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) read with SEBI Circular CIR / CFD / CMD /4/2015 dated September 09, 2015

Dear Sir / Madam,

With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Thursday, January 15, 2026 has *inter-alia* transacted, considered and approved the following business:

- The Un-Audited Financial Results (Standalone and Consolidated) along with the Limited Review Report of the Company for the quarter ended January 15, 2026 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Limited Review Report is annexed hereto and marked as Annexure I.)
- Accepting the Resignation tendered as on 5th November, 2025 by Mr. Ajay Samant- Chief Financial Officer of the Company to be effective from 31st January, 2026. (Resignation Letter along with detail reason of resignation attached in Annexure II.)
- Taking note of Resignation tendered by Ms. Anuradha Pandey- Company Secretary & Compliance Officer of the Company on 2nd January, 2026. (Resignation Letter along with detailed reason of resignation is attached in Annexure III.)

Pursuant to Regulation 33(3)(d) of the Listing Regulations, we hereby declare that in respect of the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended January 15, 2026, the statutory Auditors have not expressed any modified opinion(s) in their Audit Reports.

The Board meeting commenced at 12:00 P.M. and concluded at 2:30 P.M.

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

We request you to take the same on your records.

Thanking You,

Yours faithfully,

For Mangalam Drugs & Organics Limited


Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086

Mangalam Drugs and Organics Limited



Regd: Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

Annexure II

Details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

S.N.	Details to be provided	Information of event
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Mr. Ajay A. Samant has tendered his resignation from the position of Chief Financial Officer (Key Managerial Personnel) of the Company vide his letter dated 5 th November, 2025. He has decided to tender his designation from this post due to health reasons.
2	Date of appointment/cessation (as applicable) & term of appointment	Last day of his services to the Company was with effect from closure of business hour of January 31, 2026
3	Brief profile (in case of appointment)	Not Applicable
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

05 November 2025

The Managing Director

Mangalam Drugs and Organics Limited

Mumbai.

Dear Sir,

Due to various health issues I would like to tender my resignation from the position as the CFO (and KMP) of Mangalam Drugs and Organics Ltd with effect from January 31st 2026. If possible kindly relieve me from the post earlier.

I request you to kindly accept my resignation and initiate the necessary formalities.

Thank you for your support.



Ajay Samant